ALPINION Launches X-CUBE 90, A High-Performance Ultrasound Diagnostic System
2.3.2021 16:00:00 EET | Business Wire | Press release
ALPINION MEDICAL SYSTEMS Co., Ltd (ALPINION), a medical ultrasound professional, announced that it will launch X-CUBE 90 in March.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005348/en/
ALPINION MEDICAL SYSTEMS launches X-CUBE 90, a high-performance ultrasound diagnostic system. X-CUBE 90 provides high-resolution diagnostic images with X+ Architecture. X-CUBE 90 is the top-tier model of X-CUBE, a brand developed by upgrading the existing E-CUBE product line. X-CUBE 90 increases data transmission capacity, data transmission speed, and data processing speed by 4, 10, and up to 14 times compared to existing products. (Photo: Business Wire)
X-CUBE 90 is the top-tier model of X-CUBE, a brand developed by upgrading the existing E-CUBE product line. Compared to the existing models, X-CUBE 90 provides a more detailed image and comfortable user interface and thus a diagnostic environment of greater efficiency.
X-CUBE 90 applied X+ Architecture, an imaging platform independently developed by ALPINION. X+ Architecture is a premium-grade imaging platform created by combining X+ Crystal signature™, a transducer technology with high sensitivity and wideband, and the company’s cutting-edge beamforming and data processing technology, X+ FIT. With ALPINION’s unique algorithm, large-size data are swiftly reorganized, thus clear and high-resolution images are provided.
In addition, X+ FIT, a hardware technology applied to X-CUBE 90, increases data transmission capacity, data transmission speed, and data processing speed by 4, 10, and up to 14 times compared to existing products.
ALPINION applied the following new technologies to X-CUBE 90:
- X+ MicroView: The vascular imaging mode that displays micro blood flow. It clearly displays low-speed blood flow, which has not been possible with Color Doppler at the fast frame rate.
- X+ pSWE: The Point Shear Wave Elastography shows objective quantified stiffness of tissue and the reliability index of a measured result is displayed, ensuring to reduce unnecessary biopsies for patients.
- X+ Assistant: With an optimal scanning protocol registered according to the guideline formulated from practical use, keystroke time is reduced by at least 50%, thus effectively decreasing examination time.
ALPINION CEO Hyunjong Park states, “We are thrilled about the launch of the new high-performance ultrasound diagnostic system, X-CUBE 90. We will continue introducing new products that meet the expectations of healthcare providers and patients around the world.”
About ALPINION MEDICAL SYSTEMS Co., Ltd.
As a subsidiary of ILJIN Group (015860.KS), a company representing South Korea in the field of parts and materials manufacturing, ALPINION MEDICAL SYSTEMS specializes in the development and supply of medical ultrasounds. By independently developing and manufacturing high-quality transducers, diagnostic, and therapeutic ultrasound systems, it is contributing to the elevation in quality of medical services.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005348/en/
Contact information
ALPINION
Selina Seo +82-2-3282-0900
marketing@alpinion.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 08:00:00 EEST | Press release
The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. The company is one of the leading suppliers of maintenance and modification serv
Seiden Law LLP States: Cambodian Businessman Leak Yim, Wrongfully Accused in Thailand, Seeks Redress in U.S. Court29.6.2026 07:00:00 EEST | Press release
Seiden Law LLP (“Seiden Law”), legal counsel for Mr. Leak Yim, a Cambodia national, and his family, announces the filing of an application in U.S. federal district court in Washington D.C., seeking court-ordered discovery to uncover the false and misleading information that may have led to mistaken prosecution in Thailand of Mr. Yim as well as his unwarranted identification to Congress as being associated with scam centers in Asia. 28 U.S.C. § 1782 (“1782”) provides powerful evidence-gathering remedies, permitting an applicant to obtain evidence in the United States to assist international proceedings. Seiden Law, a U.S. law firm with significant experience in 1782 cases, has filed this application to compel production of documents and sworn testimony from persons in the U.S. that will shed light on the circumstances surrounding recent actions against Mr. Yim. “Mr. Yim and his young family are the apparent victims of guilt by association and political persecution,” said Robert Seiden,
Sultan Bin Ahmed Attends Media Master's Graduation in Spain28.6.2026 19:40:00 EEST | Press release
His Highness Sheikh Sultan bin Ahmed bin Sultan Al Qasimi, Deputy Ruler of Sharjah and President of the University of Sharjah (UOS), attended on Friday, at the University of Barcelona, the graduation ceremony of the first cohort of the Master of Science in Media Entrepreneurship and Digital Innovation programme, first of its kind, offered by the University of Sharjah's College of Communication in partnership with the University of Barcelona and with strategic support from Sharjah Media City (Shams). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628429537/en/ Sultan Bin Ahmed attends Media Master's Graduation in Spain (Photo: AETOSWire) His Highness expressed his pride in their achievements and praised the strong partnership between the two universities, which share a commitment to knowledge, excellence and global understanding. His Highness stressed that graduation marks the beginning of a new journey rather than its con
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom